13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002043476
Total reported value
$213.0M
$213.0M
20 檔
42.8%
During the Q3 2025 filing period, B Group, Inc. (CIK: 0002043476) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $213.0M across 20 reported positions.
In Q3 2025, B Group, Inc. displayed an active expansion posture, initiating 5 new positions and adding to 10 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ADMA | Adma Biologics Inc | Stock-Healthcare | 26.02% | -8.61% | +4.10% | |
| 2 | LLY | Eli Lilly & Co | Stock-Healthcare | 12.63% | — | — | |
| 3 | NVDA | Nvidia CORP | Stock-Tech | 10.29% | — | — | |
| 4 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 9.97% | -2.26% | — | |
| 5 | AKRO | Akero Therapeutics Inc | Stock-Other | 8.12% | — | — | |
| 6 | CLLS | Cellectis - Adr | Stock-Other | 6.88% | -3.09% | +0.77% | |
| 7 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 4.33% | -0.21% | — | |
| 8 | ASMB | Assembly Biosciences Inc | Stock-Other | 3.31% | -1.34% | -7.21% | |
| 9 | ✓ | Nrx Pharmaceuticals Inc | Stock-Other | 3.28% | — | — | |
| 10 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.99% | +0.02% | +22.73% | |
| 11 | AURA | Aura Biosciences Inc | Stock-Other | 2.60% | -0.41% | — | |
| 12 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 2.39% | -0.97% | — | |
| 13 | SGHT | Sight Sciences Inc | Stock-Other | 2.35% | -0.99% | — | |
| 14 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.23% | -0.82% | +25.00% | |
| 15 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.23% | -2.72% | -10.00% | |
| 16 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.06% | +0.62% | — | |
| 17 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.02% | -0.47% | EXIT | |
| 18 | REPL | Replimune Group Inc | Stock-Other | 0.15% | -0.15% | EXIT | |
| 19 | GAME | Gamesquare Holdings Inc | Stock-Other | 0.12% | — | — | |
| 20 | INSM | Insmed Inc | Stock-Healthcare | 0.02% | — | -99.90% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CLLS | Cellectis - Adr | +3.4% | +0.77% | Add |
| 2 | TSHA | Taysha Gene Therapies Inc | +2.8% | — | Add |
| 3 | ASMB | Assembly Biosciences Inc | +1.7% | -7.21% | Trim |
| 4 | RARE | Ultragenyx Pharmaceutical In | +1.5% | +22.73% | Add |
| 5 | SGHT | Sight Sciences Inc | +0.6% | — | Add |
| 6 | PRAX | Praxis Precision Medicines I | +0.6% | -10.00% | Add |
| 7 | ORKA | Oruka Therapeutics Inc | +0.6% | — | Add |
| 8 | SYRE | Spyre Therapeutics Inc | +0.3% | +25.00% | Add |
| 9 | AURA | Aura Biosciences Inc | +0.2% | — | Add |
| 10 | APGE | Apogee Therapeutics Inc | +0.1% | — | Add |
| 11 | AKRO | Akero Therapeutics Inc | -0.3% | — | Trim |
| 12 | IOVA | Iovance Biotherapeutics Inc | -1.9% | — | Unchanged |
| 13 | ZLAB | Zai Lab Ltd-adr | -2.4% | — | Unchanged |
| 14 | ADMA | Adma Biologics Inc | -13.4% | +4.10% | Add |
| 15 | INSM | Insmed Inc | -17.1% | -99.90% | Trim |
| 16 | LLY | Eli Lilly & Co | — | NEW | New buy |
| 17 | NVDA | Nvidia CORP | — | NEW | New buy |
| 18 | ✓ | Nrx Pharmaceuticals Inc | — | NEW | New buy |
| 19 | BNTX | Biontech Se-adr | — | EXIT | Sold out |
| 20 | ✓ | Ultragenyx Pharmaceutical In | — | EXIT | Sold out |
| 21 | ETNBGBP | 89bio Inc | — | EXIT | Sold out |
| 22 | ✓ | Corvus Pharmaceuticals Inc | — | EXIT | Sold out |
| 23 | REPL | Replimune Group Inc | — | NEW | New buy |
| 24 | GAME | Gamesquare Holdings Inc | — | NEW | New buy |
According to official SEC Form 13F filings, B Group, Inc. reported a total U.S. public equity portfolio value of $213.0M across 20 disclosed positions in Q3 2025.
During Q3 2025, B Group, Inc.'s top holdings by market value included ADMA (26.0%)、LLY (12.6%)、NVDA (10.3%). The largest single position, ADMA, represented 26.0% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ADMA, LLY, NVDA) accounted for 42.8% of total reported equity market value during Q3 2025.
Top New Position Initiated
LLY
市值: $17.2M
Top Position Liquidated / Trimmed
BNTX
前期市值: $1.4M
In Q3 2025, B Group, Inc. made 22 total portfolio adjustments, initiating 5 new buys, adding to 10 positions, trimming 3 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.